Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Tool Uses Imaging Data to Detect Less Frequent GI Diseases

By LabMedica International staff writers
Posted on 05 Nov 2024

Artificial intelligence (AI) is already being utilized in various medical fields, demonstrating significant potential in aiding doctors in diagnosing diseases through imaging data. More...

However, training AI models requires large datasets, which are typically abundant for common diseases. The real challenge lies in accurately detecting rarer diseases, which many current AI models tend to overlook or misclassify. Researchers have now created a new AI tool designed to utilize imaging data to identify less common gastrointestinal tract diseases effectively.

Developed by scientists at Ludwig Maximilian University of Munich (Munich, Germany) and their collaborators, this innovative model only requires training data from frequently observed conditions to reliably detect rarer diseases. This advancement has the potential to enhance diagnostic accuracy and alleviate the workloads of pathologists in the future. As reported in the New England Journal of Medicine AI (NEJM AI), the new technique is founded on anomaly detection. The model learns to identify and highlight deviations from the precise characterization of normal tissues and findings from common diseases, without the need for specific training on these less frequent cases. The researchers utilized a dataset of 17 million histological images from 5,423 cases for training and evaluation.

In their research, the team gathered two extensive datasets of microscopic images from gastrointestinal biopsy tissue sections, along with their corresponding diagnoses. In these datasets, the ten most common findings—including normal observations and prevalent diseases such as chronic gastritis—constituted approximately 90% of cases, while the remaining 10% encompassed 56 different disease entities, including various cancers. Additionally, the AI model employs heatmaps to visually indicate the location of anomalies within the tissue section. By distinguishing normal findings and common diseases while detecting anomalies, the AI model is poised to offer crucial support to healthcare professionals. Although the identified diseases still require validation by pathologists, this AI tool can significantly reduce diagnostic time, as it enables automatic diagnosis of normal findings and a portion of diseases.

“We compared various technical approaches and our best model detected with a high degree of reliability a broad range of rarer pathologies of the stomach and colon, including rare primary or metastasizing cancers. To our knowledge, no other published AI tool is capable of doing this,” said Professor Frederick Klauschen, Director of the Institute of Pathology at LMU.


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.